The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2025 | Resistance in CLL: high-risk features and strategies to overcome this challenge
Meghan Thompson, MD, Memorial Sloan Kettering Cancer Center, New York, NY, shares insights into the high-risk features of chronic lymphocytic leukemia (CLL) that persist in the relapsed setting. She also highlights emerging resistance to targeted therapies, particularly BTK inhibitors, and discusses strategies to overcome this challenge, including alternative agents, combination approaches, and fixed-duration treatments. This interview took place at the 13th Annual Meeting of the Society of Hematologic Oncology (SOHO 2025) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
